PART 1
Overview of Part 1
What treatments did the participants get during Part 1?
There were 40 participants in Part 1. All of them got durvalumab and
tremelimumab for the first 4 treatments, then durvalumab on its own.
What were the results of Part 1?
The main questions the researchers wanted to answer in Part 1 were:
X What signs and symptoms did the participants have during Part 1?
The most common symptom that the participants had during
Part 1 was diarrhea. This may or may not have been caused by the
study drugs.
X What medical problems happened during Part 1?
In Part 1, 65.0% of participants had medical problems that the
study doctors thought might be related to the study drugs. The
most common medical problem was fatigue.
More details about the answers to these questions can be found later in
this summary.
5 | Clinical Study Results